A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt), Each Administered as a Single Oral Dose

Trial Profile

A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt), Each Administered as a Single Oral Dose

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2014

At a glance

  • Drugs Deferitazole (Primary)
  • Indications Iron overload
  • Focus Pharmacokinetics
  • Sponsors Shire
  • Most Recent Events

    • 07 Aug 2014 Status changed from suspended to withdrawn prior to enrolment reported by ClinicalTrials.gov.
    • 18 Mar 2014 Status changed from not yet recruiting to suspended as reported by ClinicalTrials.gov record.
    • 01 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top